Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Snehal Patel, CEO and CFO of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), just lately bought 3,200 shares of frequent inventory in a transaction dated December 30, 2024. The shares had been acquired at a worth of $11.12 per share, totaling $35,584. The transaction comes as the corporate, at present valued at roughly $148 million, trades close to $11.23 per share. In accordance with InvestingPro evaluation, the inventory seems overvalued at present ranges. Following this transaction, Patel’s direct possession within the firm elevated to five,539,302 shares. This acquisition displays Patel’s continued involvement and funding within the pharmaceutical firm headquartered in Stafford, Texas. The inventory has proven important volatility, with analysts setting a goal worth of $38 per share. InvestingPro subscribers can entry further insights, together with 7 extra ProTips and detailed monetary metrics for GLSI.
In different current information, Greenwich LifeSciences reported the outcomes of its Annual Assembly of Stockholders, which included important developments. The pharmaceutical firm introduced the re-election of all 5 director nominees, showcasing sturdy assist with over 7.8 million votes for every director. The corporate’s unbiased registered public accounting agency, RBSM, LLP, was ratified for the fiscal 12 months ending December 31, 2024.
A notable modification to the corporate’s 2019 Fairness Incentive Plan was authorised, growing the variety of shares reserved for issuance to 4,000,000 from the earlier 1,500,000 shares. The outcomes of those proposals replicate the shareholders’ assist for the corporate’s present management and strategic initiatives.
InvestingPro’s evaluation signifies the corporate, regardless of not being at present worthwhile, has a set worth goal of $38, suggesting a possible upside. These current developments are anticipated to information Greenwich LifeSciences in its ongoing efforts inside the healthcare sector.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.